FNY Investment Advisers’s Exagen XGN Stock Holding History

FNY Investment Advisers’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-200	Closed	-$3K	–	1099
2019 Q3	$3K	Buy	+200	New	+$3.23K	﹤0.01%	706

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

FNY Investment Advisers's XGN Position: Q4 2019 in Review

FNY Investment Advisers sold out of Exagen (XGN) in Q4 2019, closing a stake of 200 shares — an estimated $3K sold.

FNY Investment Advisers first reported a position in XGN in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 36 funds tracked by Wall St. Rank hold XGN as of Q4 2019.

FNY Investment Advisers reported no remaining Exagen position as of Q4 2019 after selling out during the quarter.
FNY Investment Advisers sold 200 Exagen shares in Q4 2019, an estimated $3K.
FNY Investment Advisers first reported a position in Exagen in Q3 2019 and held it in 1 quarter.
FNY Investment Advisers's Exagen position peaked at $3K in Q3 2019.
36 funds tracked by Wall St. Rank held Exagen as of Q4 2019.

Based on FNY Investment Advisers's 13F filing for Q4 2019, filed 10 Jan 2020.